@article{62e58054227d4f8394c8c5be39e3e5ab,
title = "Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity",
abstract = "T cell exhaustion presents one of the major hurdles to cancer immunotherapy. Among exhausted CD8+ tumor-infiltrating lymphocytes, the terminally exhausted subset contributes directly to tumor cell killing owing to its cytotoxic effector function. However, this subset does not respond to immune checkpoint blockades and is difficult to be reinvigorated with restored proliferative capacity. Here, we show that a half-life-extended interleukin-10–Fc fusion protein directly and potently enhanced expansion and effector function of terminally exhausted CD8+ tumor-infiltrating lymphocytes by promoting oxidative phosphorylation, a process that was independent of the progenitor exhausted T cells. Interleukin-10–Fc was a safe and highly efficient metabolic intervention that synergized with adoptive T cell transfer immunotherapy, leading to eradication of established solid tumors and durable cures in the majority of treated mice. These findings show that metabolic reprogramming by upregulating mitochondrial pyruvate carrier-dependent oxidative phosphorylation can revitalize terminally exhausted T cells and enhance the response to cancer immunotherapy.",
author = "Yugang Guo and Xie, {Yu Qing} and Min Gao and Yang Zhao and Fabien Franco and Mathias Wenes and Imran Siddiqui and Alessio Bevilacqua and Haiping Wang and Hanshuo Yang and Bing Feng and Xin Xie and Sabatel, {Catherine M.} and Benjamin Tschumi and Amphun Chaiboonchoe and Yuxi Wang and Weimin Li and Weihua Xiao and Werner Held and Pedro Romero and Ho, {Ping Chih} and Li Tang",
note = "Funding Information: We thank D. Trono and B.E. Correia for providing plasmids of Delta 8.9 and pVSV-G; J.-C. Martinou (University of Geneva) for providing Mpc1fl/fl mice; and A. Donda (University of Lausanne) for the technical support on human CAR T cells. We acknowledge the EPFL Center of PhenoGenomics, Flow Cytometry Core Facility and Protein Expression Core Facility for technical assistance. This work was supported in part by the Swiss National Science Foundation (SNSF project grant no. 315230_173243), the ISREC Foundation with a donation from the Biltema Foundation, the Swiss Cancer League (grant no. KFS-4600-08-2018), the European Research Council under the ERC grant agreement MechanoIMM (grant no. 805337), the Kristian Gerhard Jebsen Foundation, Fondation Pierre Mercier pour la science, an Anna Fuller Fund grant and the EPFL (L.T.). P.-C.H. was supported in part by the Swiss Institute for Experimental Cancer Research (ISREC grant no. 26075483), SNSF project grants (grant nos. 31003A_163204 and 31003A_182470), the Cancer Research Institute Lloyd J. Old STAR award and the European Research Council Starting Grant (grant no. 802773-MitoGuide). P.R. was supported in part by grants from the SNSF (grant nos. 310030_182735 and 310030E-164187). W.H. was supported in part by the Swiss Cancer League (grant no. KFS-4407-02-2018) and the SNSF (grant no. 310030B_179570). W.X. was supported in part by the Strategic Priority Research Program of the Chinese Academy of Sciences (grant no. XDB29030000) and the Ministry of Science and Technology of China (grant no. 2016YFC1303503). M.G. was supported by the Chinese Scholarship Council (grant no. 201808320453). Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.",
year = "2021",
month = jun,
doi = "10.1038/s41590-021-00940-2",
language = "English (US)",
volume = "22",
pages = "746--756",
journal = "Nature Immunology",
issn = "1529-2908",
publisher = "Nature Publishing Group",
number = "6",
}